FDA postpones review of child COVID-19 vaccine

The Food and Drug Administration on Friday postponed an advisory meeting on Pfizer-BioNTech’s vaccine for young children and will wait for data on the third dose from trials, meaning the rollout for ages 0 to 4 might not begin until April.

Senior officials said the FDA decided to scrap the ...